Background: Two vaccines against Clostridioides difficile infections (CDI) are currently in phase III trials. To enable decision-making on their use in public health programs, national disease epidemiology is necessary.
Introduction
Clostridioides difficile is the most frequent cause of healthcareassociated infectious diarrhea in Canada and other industrialized countries (1) . In the United States, it affects more than 300,000 hospitalized patients yearly (2) . Symptoms of C. difficile infection (CDI) range from mild diarrhea to severe life-threatening inflammation of the colon (3) . In Canada, many provinces SURVEILLANCE initiated CDI surveillance programs following a dramatic increase in incidence and severity in the early 2000s, and in response to CDI becoming a national notifiable disease in 2009 (4) . In parallel, the Canadian Nosocomial Infections Surveillance Program (CNISP) network (2), a sentinel network of 67 primarily tertiary teaching hospitals in urban centers, has participated in hospital-acquired and community-associated CDI surveillance (5) . Most provinces use hospital-acquired CDI as one of the indicators assessing health system performance and patient safety. The main objective of provincial surveillance programs is to determine the incidence of hospital-acquired CDI and to monitor trends and patterns in CDI over time, in order to prevent and control disease (6) (7) (8) (9) (10) (11) (12) (13) (14) . However, in 2015, the Canadian Communicable Disease Steering Committee's Antimicrobial Resistance Surveillance Task Group identified several surveillance gaps in CDI surveillance activities, most notably gaps in data from community settings (4, 15) .
Two C. difficile vaccines are currently in phase III trials worldwide (16, 17) . To enable decision-making on the potential use of these vaccines in public health programs, considering the Erickson-DeWals-Farand analytical framework (18) and methods of the National Advisory Committee on Immunization (19) for immunization programs decisions in Canada, national disease epidemiology is a critical factor. Although the Public Health Agency of Canada provides annual national healthcareassociated CDI surveillance reports, the data are primarily derived from large, tertiary acute care hospitals and may not be representative of all hospital types and jurisdictions (5, 20) . There has never been a study conducted systematically on provincial CDI surveillance programs in Canada. Additionally, since healthcare-and thus hospital-acquired infection-is under provincial/territorial jurisdiction, discrepancies in definitions, surveillance methodologies, available laboratory diagnostics and variation in the validation of surveillance programs may exist, hence rendering inter-provincial/territorial comparison difficult.
The objectives of this study were to determine the epidemiology of hospital-acquired CDI (HA-CDI) and community-associated CDI (CA-CDI) as it pertains to Canada, using provincial surveillance data from 2011 to 2016 and to document discrepancies in CDI-related definitions among the provincial surveillance programs.
Methods

Study population
The study population included fiscal-year C. difficile infection surveillance in Canada from 2011 to 2016 at the provincial/ territorial level. All of Canada's provinces and territories were potential participants in the study. To be included, the jurisdiction needed to have a surveillance system that distinguished between HA-CDI and CA-CDI.
Definitions
The definitions related to CDI have been well-described (6) (7) (8) (9) (10) (11) (12) (13) (14) . For the purpose of this study, definitions for HA-CDI and CA-CDI used included the most common descriptions shared by the ten provinces (Text box). The HA-CDI and CA-CDI definitions, case classification, population surveilled, denominator definition and sources, and laboratory confirmation requirements were extracted separately from provincial protocols for comparison. Surveillance definitions varied from province to province and type of discrepancies were summarized.
Data collection
Data were extracted from provincial public reports retrieved from the Internet in July 2018. Data missing (i.e. number of HA-CDI cases and total inpatient days for Nova Scotia) were requested via email directly from the provinces (i.e. Nova Scotia's Freedom of Information and Protection of Privacy Act) in June/July 2018, with answers received in July 2018. For more specific data on the search strategy, please refer to Appendix A. All data were published or requested through legal access with the consent of the province.
Statistical analysis
When available, HA-CDI incidence rates per 10,000 inpatientdays, pooled HA-CDI incidence rates per 10,000 inpatient days, CA-CDI incidence rates per 100,000 population and CA-CDI proportions (%) were recorded. If no incidence rates existed in the provincial reports, the HA-CDI incidence rates and CA-CDI incidence rates were calculated from available data. Pooled HA-CDI incidence rates for the entire study period were calculated for each province. The CA-CDI proportions were generated for provinces with numbers of CA-CDI cases and total CDI cases available. Both HA-CDI incidence rates and CA-CDI incidence rates were examined for trends.
Definitions
Hospital-acquired Clostridium difficile infection (HA-CDI)
HA-CDI was defined as:
• a primary CDI case in an inpatient, with symptom onset at least 72 hours, or more than three calendar days, after admission to the reporting facility OR • a primary CDI case, with symptom onset in the community or occurring less than 72 hours or less than or equal to three calendar days after admission to the reporting facility, who was discharged from the reporting facility in the four weeks prior to the current hospitalization (6-14)
Community-associated Clostridium difficile infection (CA-CDI)
CA-CDI was defined as:
• a CDI case with symptom onset in the community OR • occurring less than or equal to 72 hours or less than or equal to three calendar days after admission to a healthcare facility, provided that symptom onset was more than four weeks after the patient was discharged from any healthcare facility
Pooled HA-CDI incidence rates and HA-CDI incidence rates were generated based on the following formula: (total number of HA-CDI cases/total inpatient days) x 10,000. Other than provinces with available total inpatient-days data used for calculating incidence rates, the denominator of that formula was back-calculated using the following formula: (number of HA-CDI cases/HA-CDI rate) x10,000. Similarly, CA-CDI incidence rates were computed using the following formula: (total number of CA-CDI cases/mid-year population) x 100,000 (mid-year data from July 1). The CA-CDI proportions were calculated using the following formula: total number of CA-CDI/total number of CDI cases reported in the province x 100%.
Results
Based on the inclusion criteria, the study included nine of the 10 provinces and no territories. One province was excluded because its surveillance system did not distinguish between HA-CDI and CA-CDI. The territories were excluded as they did not have existing CDI surveillance programs.
Hospital-acquired incidence rates
The HA-CDI incidence rates by year and province and pooled HA-CDI incidence rates are presented in Table 1 with additional detail in Appendix B. The HA-CDI incidence rates by year indicated that, for almost all provinces, trendlines had been decreasing. In contrast, rates in Newfoundland and Labrador had been increasing, rates in Prince Edward Island had been rising slightly and no obvious trends were seen for New Brunswick and Nova Scotia. Pooled HA-CDI incidence rates showed that Quebec and British Columbia had relatively higher rates, at 6.5/10,000 and 5.3/10,000 inpatient-days, respectively, followed by Alberta (3.8/10,000 inpatient-days) and Prince Edward Island (3.0/10,000 inpatient-days) (Appendix C: Figure C-1) . The other provinces (Ontario, Nova Scotia, Saskatchewan, New Brunswick and Newfoundland and Labrador) each had rates of less than 3/10,000 inpatient-days.
Community-associated incidence rates
Only Alberta, British Columbia, Newfoundland and Labrador, Prince Edward Island, Quebec and Saskatchewan had publiclyaccessible CA-CDI data. Alberta was excluded from this part of the study, since it posted only rates and utilized a unit that was different from the one used in this study (per 100,000 population versus per 1,000 admissions).
The CA-CDI incidence rates and CA-CDI proportions for provinces are presented in Table 2 with additional detail in Appendix B. In contrast to the HA-CDI incidence rates trends, the CA-CDI incidence rates of all five provinces examined (with the exception of Prince Edward Island) increased (Appendix C: Figure C -2). For Newfoundland and Labrador and Prince Edward Island, there were marked increases in CA-CDI incidence rates from 2012-2013 to 2014-2015. The same trend was also seen for CA-CDI proportions in British Columbia and Quebec. Even though the CA-CDI proportions in Newfoundland and Labrador were declining over the time period of the study, and the proportion seemed to be increasing in Prince Edward Island, the overall CA-CDI case counts in both provinces still represented a large portion of the total CDI cases reported.
Discrepancies
In the process of data collation and analysis, discrepancies among provincial surveillance definitions of CDI case classification, surveillance populations and rate calculation were detected, which impeded comparison of CDI rates between provinces. The fundamental issue was that each province defined and complied with its own protocol, leading to highly varied numerators (number of CDI cases) and denominators (total inpatient-days). A summary of discrepancies with examples are shown in Table 3 . For a more detailed description of the different definitions by provincial surveillance programs, refer to Appendix D. We were unable to use the Canadian Institute for Health Infomation (CIHI) Management Information System (MIS) database to estimate the denominators due to the differences in total inpatient days between CIHI and provincial surveillance programs. The differences between the data in the CIHI MIS database and denominators adopted by provinces varied plus or minus 5% to 10%. We were unable to match denominators that fit the definitions of provinces from the CIHI database. For detailed differences between denominators estimated from the CIHI MIS database and those used by provinces, and the calculations used to extract the denominators, please refer to Appendix B. 
Discussion
From 2011 to 2016, the HA-CDI incidence rates in most provinces decreased, which is consistent with the trend reported by the Canadian Antimicrobial Resistance Surveillance System and a study based on the CNISP network (21, 22) . This reduction in rates might be attributed to infection prevention and control interventions (e.g. hand hygiene, environmental cleaning, patient-dedicated toilets and single-patient rooms), antibiotic stewardship and increased CDI awareness. The reduction in the proportion of NAP1 isolates (22) , which has been the predominant strain in Canada associated with increasing rate of severe HA-CDI, may also have played an important role.
On the other hand, despite the possibility of an actual increase in CDI cases, the increased incidence rates could be partly explained by the evolution of circulating strains, which might lead to increased toxigenic potential and survival of the bacteria, or to improvements in surveillance and reporting in the province. Notwithstanding the slightly increasing trend in New Brunswick and Nova Scotia, there were only three years of data available for New Brunswick and only the fourth quarter of 2011-2012 fiscal year data available for Nova Scotia, decreasing our power to conclude on trends of HA-CDI incidence rate in these two provinces.
Even though most CA-CDI cases were reported in admitted patients, trends, not absolute rates, were studied in this article. Therefore, choosing the provincial population or admissions as the denominator had only a minor impact on the results. The five provinces included in the analysis of CA-CDI incidence rates showed a slight, increasing trend. Of the nine provinces, almost all focused only on HA-CDI. However, the observation of these trends in HA-CDI indicated the importance of also monitoring and analyzing CA-CDI in future surveillance activities. Improved surveillance and reporting from the community may explain these trends. Moreover, the mutual effect of decreasing numbers of HA-CDI cases, growing numbers of CA-CDI cases, and increased use of nucleic acid amplification testing may also explain the observed trends. Population under surveillance
The population under surveillance in British Columbia is defined as "inpatients aged one year or older and admitted to acute care facilities", while some provinces monitor "any patient with a laboratory-confirmed CDI in the province".
Quebec excludes from surveillance patients in long-term care facilities. Only cases admitted to acute care hospital, from long-term care would be included; it is not clear if the same is done everywhere.
Classification of cases
While some of the provinces only report hospitalacquired CDI or only monitor new cases, some classify CDI cases into more refined categories: the category of "related to reporting facility" is further stratified into "related to current/previous hospitalization"; "another facility" is stratified into "long-term/ambulatory care and non-reporting"; and also, "new" and "recurrent" cases are documented separately.
All HA-CDI cases might be classified into a single category or could be separated in two: acute care facility-acquired or long-term care facility-acquired.
CA-CDI surveillance: Quebec only reports hospitalized cases; it is unclear what is done elsewhere.
Definition for the cases classifications
Even though the same categories of CDI cases were monitored, they might have different denominators and case definitions. For example, most provinces define HA-CDI as symptoms occurring more than 72 hours after admission, while Manitoba defines HA-CDI as 48 hours after admission.
Denominators used for calculating the rates
In some jurisdictions, patients less than one year of age (or a proxy of that) and/or psychiatric patients were excluded. Meanwhile, some provinces use the total number of inpatient-days regardless of age or area of care.
In some instances, the denominator was estimated from other provincial data sources and might be adjusted to fit CDI rate reporting.
Denominators used by the provinces and CIHI MIS database
Unable to generate the denominators used by the provinces using the data available in CIHI MIS database.
Some provinces used denominators that were higher than the total inpatient-days showed in CIHI MIS database.
an increase in the proportion of CA-CDI cases, even though the overall numbers (HA-CDI plus CA-CDI cases) remain stable, while the increased testing could contribute to the detection of more CA-CDI cases, which were not tested for in the past. In Newfoundland and Labrador and Prince Edward Island, CA-CDI cases still accounted for a relatively high percentage of all CDI cases reported.
The introduction of more sensitive laboratory testing methods, such as polymerase chain reaction, which detects the toxigenic potential but not the actual toxin production, has been associated with increasing numbers of positive tests and earlier detection compared with enzyme-linked immunosorbent assay (23, 24) . Currently, although all the provinces required clinical validation for the identification of CDI cases, the test methods used for this validation varied. Moreover, laboratory tests and protocols have changed over the years, and the impact of these changes on the accuracy of CDI rates is difficult to assess.
Limitations
There are a number of limitations to consider. Given the shortage of data, we were limited in the analyses that could be performed. Optimally, comparisons between the provinces and stratified analyses, such as incidence rates by age strata, underlying medical conditions and sex, are performed to determine high-risk populations and to provide useful information for cost-effective analyses that could support future CDI vaccine decision-making processes. Unfortunately, these comparisons and analyses could not be performed fully due to the tremendous disparities among the current provincial surveillance systems (Appendix D).
Another limitation was the discrepancy in the denominators (total inpatient-days) used to calculate HA-CDI rates; discrepancies among the provinces and also between the provinces and the CIHI MIS database. The CIHI database was initially considered for providing a relatively accurate estimation of total inpatientdays. This was because these data were reported on the basis of the fiscal year and are representative of the inpatient population during that year. However, it was found that denominators used by the provinces to calculate their provincial CDI rates were different from the denominators in the CIHI MI database. Furthermore, later comparisons showed a divergence between CIHI data and CNISP denominators. One of the reasons for this difference is that the definitions for denominators derived from the CIHI database did not match those used by either the provinces or CNISP. This suggested that total inpatientdays reported to CIHI and those used for provincial CDI rate calculations were derived from different reporting systems. The target population contributing to the total inpatient-days might vary as well. Because it was not clear how the provinces generated the total inpatient-days, these discrepancies cannot be fully explained. Further research and collaboration is needed to identify the cause of and to solve this discrepancy.
It should also be noted that the data retrieved from provinces through this analysis did not include laboratory-linked strain data for CDI cases. This is a major limitation and prevents the monitoring of ecological trends over time with varied CDI strain types.
Although two potential vaccines are currently undergoing clinical trials, it is not yet known how broadly protective these candidate vaccines will be against the various C. difficile strains or the potential mutants escaped from being detected by traditional strategy. The CNISP has already revealed important trends in virulent strains and antimicrobial resistance (5, 22) . However, as previously discussed, CNISP is limited to data primarily from a small sample of large, tertiary acute care hospitals across Canada and thus does not provide a complete picture.
Missing data were an important limitation in our study. Only Quebec provided data of total inpatient-days that met the definition of their CDI surveillance protocol. For the other provinces, although some total inpatient-days data might have appeared in the provincial reports, none matched those used to calculate HA-CDI rates. Although, as demonstrated in this paper, denominators can be estimated by back-calculation, this erodes the reliability and accuracy of data presented.
Next steps
There is a fundamental need for a nationally-adopted CDI surveillance protocol. This type of surveillance would be the single most important way to address the many discrepancies between provinces, arising from highly varied data-numerators (number of CDI cases), denominators (total inpatient-days) and different definitions for populations under surveillance-that make incidence rates difficult to compare and interpret.
To provide national-level epidemiological data to support decision-makers in their recommendations for the implementation of a potential CDI vaccine program, several key elements are needed. First, demographically-stratified incidence rates, including delineation by age and sex, would be useful to determine whether certain at-risk groups would benefit more from the vaccine. A study conducted in Spain (22, 25) showed that CDI evolves differently by sex and age group. Second, as mentioned in the CNISP Summary Report (2) and as shown in our study, recurrent and CA-CDI should be monitored to increase the understanding of the burden, risk factors and outcomes of such infections in Canada. Third, the use of a common, nationally-adopted definition for CDI, CDI categories and total inpatient-days is critical; the CNISP CDI case definition (26) could be adopted for this purpose, with standardized data collected and reported. Fourth, a quality assessment system is needed to ensure quality of reported data. Fifth, CIHI could be an ideal partner to provide data for total inpatient-days, given its already well-established data gathering system from provinces. The CIHI is able to provide the general total inpatient-days that fit the SURVEILLANCE selected definition, allowing for validation of provincial data, and could be an excellent source for stratified inpatient-days. Finally, the ideal solution would be a national online reporting system that includes universal case definitions, and all hospitals across Canada could provide standardized and comparable data that would be accessed and reported via an online platform, allowing for local, regional, provincial and national comparisons. This would not only simplify the study of the epidemiology of different diseases at different levels and make it more feasible to gather case characteristics to gain a complete view of the disease, but it would provide better control of the overall quality of the information as well.
In our interconnected open-data era, this would meet the heightened expectation of timely and publicly-accessible surveillance data. One way to do this would be by expanding CNISP, the Public Health Agency of Canada's sentinel surveillance program that uses a data entry platform on the Canadian Network for Public Health Intelligence (CNPHI), but there may be other equally valid means of collecting CDI surveillance data.
Conclusion
In Canada, the rate of HA-CDI has generally been decreasing but the rate of CA-CDI is increasing. There are important discrepancies in CDI-related definitions among provincial surveillance programs that impede comparisons of CDI rates between provinces, and calculating a pan-Canadian burden of illness to support vaccine program decision-making. 
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This study did not receive any funding. (2) A CDI case occurring more than 72 hours or more than three calendar days (the day of admission counted as the first calendar day, the same hereinafter) after admission to an acute care facility cases identified on or after the fourth calendar day of hospitalization will be classified as HCA)
OR
A CDI case with symptom onset in the community or occurring fewer than or equal to 72 hours or fewer than or equal to three calendar days after admission to an acute care facility, provided that the patient was admitted to a healthcare facility (including acute care and long-term care) for a period of more than or equal to 24 hours or at least overnight stay in the past four weeks before onset of CDI symptoms A case in which symptoms occur at least 72 hours or more after the current admission OR Symptoms occur in a patient who has been hospitalized at a hospital and discharged within the previous four weeks Nova Scotia (6) The patient's CDI symptoms occur in your healthcare facility three or more days after admission, with day of admission being day one OR The patient's CDI symptoms occur less than three days after admission and are seen in a patient who had been hospitalized at a healthcare facility and discharged within the previous four weeks Ontario (7) Onset of symptoms more than 72 hours after admission
The infection was present at the time of admission but was related to a previous admission to the same facility within the last four weeks and the case has not had Clostridium difficile-associated disease in the past eight weeks Prince Edward Island (8) Symptoms were not present on admission (onset of symptoms more than 72 hours after admission) and there was no admission to an acute care or long term care facility in the last four weeks (if the patient/resident was in another facility in the past four weeks, the case may be attributed to that facility)
Not mentioned in the guideline or other reports Quebec (9) Patients hospitalized on a short-term care unit of the reporting facility AND diagnosed with CDAD three days and more (so starting on D4) after admission (admission=D1) OR Long-term or psychiatric patients hospitalized in short-term units three days or more after admission (D4)
• Excluded: patients hospitalized on registered psychiatric, neonatal and children's complete long-term care units Patients hospitalized or not in the reporting facility and diagnosed with CDAD up to four weeks after their release from a short-term care unit of the reporting facility whatever the length of hospitalization OR Patients transferred to a residential and long-term care centre or private residence providing care and diagnosed with CDAD up to four weeks after their release from a short-term care unit of the reporting facility whatever the length of hospitalization whether they are re-admitted to the reporting facility or not OR Patients transferred to a general hospital specialty clinic (other participating short-term care centre) or rehabilitation centre, participating in monitoring or not, and diagnosed with CDAD less than three days (so D1, D2 or D3) after their admission/registration in emergency (D1)
• Excluded: patients transferred to a short-term care centre or rehabilitation centre, participating in monitoring or not, and diagnosed with CDAD three days and more after admission (so starting on D4) after their transfers (these cases will then be attributed to the centre to which each patient was transferred)
Saskatchewan (10) The patient's CDI symptoms began more than or equal to three days after admission to the reporting healthcare facility OR The patient's symptoms began in the community or fewer than three days after admission to the reporting facility
AND
The patient was admitted to the reporting facility for a period of more than or equal to three days in the past four weeks 
SURVEILLANCE
Province Definition
Alberta (1) Any primary CDI case not meeting the criteria for the hospital-acquired or healthcare-associated will be considered community acquired British Columbia (2) A CDI case with symptom onset in the community or occurring within fewer than or equal to 72 hours or fewer than or equal to three calendar days after admission to an acute care facility, provided that the patient was not admitted to any healthcare facility (including acute care and long-term care) for a period of more than or equal to 24 hours or at least overnight stay in the past four weeks before onset of CDI symptoms (5) A case with symptom onset in the community or three calendar days or less after admission to a healthcare facility, provided that symptoms onset was more than four weeks after the last discharge from a healthcare facility Nova Scotia n/a Ontario n/a Prince Edward Island (8) Symptom onset in the community or fewer than 72 hours after being admitted to an acute care or long term care facility, and symptom onset was more than four weeks post-discharge from an acute care/long term care facility Not mentioned in the guideline or other reports
Quebec (9) Patients hospitalized on a short-term care unit of the reporting facility and diagnosed with CDAD less than three days (so D1, D2 or D3) after admission/registration in emergency and having no connection with the care environment (hospital, residential centre or ambulatory services included in categories 1b, 1c, 1d and 2) within the preceding four weeks (28 days) Saskatchewan (10) CDI symptoms began in the community or fewer than three days after admission to a healthcare facility, provided that symptom onset was more than four weeks after the patient was discharged from any healthcare facility CA-CDI cases do NOT need to be entered into the CDI Electronic Report Form-might underestimate the number of CA-CDI cases Abbreviations: C. difficile, Clostridioides difficile; CA-CDI, community-associated CDI; CDAD, Clostridium difficile associated diarrhea; CDI, Clostridioides difficile infections; n/a, data not available Note: Bolded text reflect subtle differences between provinces In the case that mental health inpatients are NOT excluded from the population under surveillance for CDI in your health authority, the cases of CDI identified among mental health inpatients should be collected and included in your CDI data submission Derived from the report, no protocol available
Newfoundland and Labrador
Not mentioned in the guideline or reports Nova Scotia (6) The total number of days that patients are in hospital ("patient days") on the units on which surveillance for CDI is conducted. This is collected on a quarterly basis. Excluded from "patient days" are dedicated long-term care, mental health/psychiatric or withdrawal management units, and patients younger than one year of age. Denominator data should be collected using the health information systems of the respective authority
Ontario (7) Total number of inpatient days The appropriate denominator used to determine CDI rates is 'patient/resident days'. Denominator data (estimated from other provincial data sources) is provided to regional Infection Control Professionals (ICPs). The ICPs may change these numbers if they are not reflective of the current situation (e.g. due to bed closures), or if the ICPs are able to refine the estimate provided. Some ICPs have submitted exact denominator data for their region and others have allowed the estimated provincial data to be used. However, given that the denominator is based on 10,000 patient days, the discrepancy between the actual denominator and the estimate would have to be fairly large to make a significant difference in the rate 
